Insights

New Report: Analyzing the Expanded Landscape of Value-Based Entities – Implications and Opportunities of Enablers for the CMS Innovation Center and the Broader Value Movement

New Report Analyzes the Expanding Landscape of Value-Based Entities     Research from HMA and LP VBP experts segments and sizes the growing enabler market, considering benefits and risks, and proposing guiding principles and policy recommendations for the CMS Innovation Center A new in-depth HMA report analyzes the landscape of emerging value-based entities and the implications … Read more

New White Paper: A Vision for the Future of Medicare Advantage Supplemental Benefits: Advancing Value, But Validating Results

Medicare Advantage plans in the United States continue to explode in popularity, now reaching over 30 million Americans, due to the broad appeal of supplemental benefits that can be offered by plans to enrollees. What started off as a core set of benefit offerings, including dental, vision, and over-the-counter medications, has recently been expanded by … Read more

New Task Force Endorses Legislation to Save Rare Disease Treatments 

The Save Rare Treatments Task Force, a new multi-sector public policy and advocacy collaboration convened by Leavitt Partners, an HMA Company, publicly launched this week and today released a letter of support for recently introduced, bipartisan, bicameral legislation. The Task Force is comprised of organizations representing persons living with rare diseases, biopharmaceutical innovators, and other … Read more

New White Paper: “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward”

In “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward,” Rebecca Nielsen, Brooke Zollinger, and Sarah Johnson from Leavitt Partners explore the feasibility of operationalizing an aggregated precision investment (API) model for social determinants of health (SDOH) interventions. The authors derive their findings from subject matter expert interviews, conversations with potential aggregators, and relevant secondary research. This article enumerates … Read more

Supporting Pharmacy Data Interoperability: An Imperative for Patient Access and Outcomes

Pharmacy provision of clinical services is important to patient access and outcomes. As patients access more services from pharmacies, the data interoperability of those pharmacies becomes more important to the healthcare system at-large. Pharmacy teams’ ability to provide optimal care and meaningfully contribute to the value-based care transformation depends on their ability to access and … Read more

Press

Press Check out the latest Leavitt Partners news, right here.